DRINABANT

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H20Cl2F2N2O2S
Molecular Weight	497.385
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(=O)(=O)N(C1CN(C1)C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)C4=CC(F)=CC(F)=C4

InChI

InChIKey=IQQBRKLVEALROM-UHFFFAOYSA-N

InChI=1S/C23H20Cl2F2N2O2S/c1-32(30,31)29(21-11-19(26)10-20(27)12-21)22-13-28(14-22)23(15-2-6-17(24)7-3-15)16-4-8-18(25)9-5-16/h2-12,22-23H,13-14H2,1H3

HIDE SMILES / InChI

Molecular Formula	C23H20Cl2F2N2O2S
Molecular Weight	497.385
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://adisinsight.springer.com/drugs/800020616 | https://www.genengnews.com/news/opiant-pharmaceuticals-to-develop-sanofis-acute-cannabinoid-overdose-candidate-drinabant/ | https://www.ncbi.nlm.nih.gov/pubmed/21181124 | https://www.ncbi.nlm.nih.gov/pubmed/20168311

Drinabant is a selective CB1 receptor antagonist under investigation varyingly as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence. Drinabant may be useful to treat the cognitive deficits in schizophrenia and as a co-treatment with currently available antipsychotics. Coadministration of olanzapine and drinabant attenuated body weight gain, diminishing the enhanced food intake while maintaining increased energy expenditure and decreased motility. Sanofi has outlicensed global development and commercialization rights to drinabant to Opiant Pharmaceuticals, which said it plans to start developing the acute cannabinoid overdose (ACO) candidate in the 2019 year. Opiant said drinabant will be developed as an injectable for administration in an emergency department setting.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cannabinoid CB1 receptor 85 Target ID: CHEMBL218 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21170298 \| https://www.ncbi.nlm.nih.gov/pubmed/21181124	Antagonist 2778		0.68 nM [Ki]

PubMed

Title	Date	PubMed
CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats.	2007 Sep	17595216
Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.	2009 Mar	19249987
Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625.	2010 Mar	18801827
Ligand Binding Sensitivity of the Extracellular Loop Two of the Cannabinoid Receptor 1.	2010 Nov 1	21170298
Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.	2010 Oct	20168311
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.	2011 May	21181124

Patents

Sample Use Guides

In Vivo Use Guide

10 mg/kg once daily

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:59:53 GMT 2023` Edited by `admin` on `Sat Dec 16 16:59:53 GMT 2023`
Record UNII	61S98RLL5I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DRINABANT

Official Name

English

drinabant [INN]

Common Name

English

Drinabant [WHO-DD]

Common Name

English

Code System Code Type Description

INN

9033